Risk factor | Univariate analysisa | Multivariate analysisc |
---|
Coefficientb | P value | Coefficient | P value |
---|
DDD |
BLBLIs | 0.07 | 0.10 | | |
Glycopeptides | − 0.16 | 0.04 | − 0.16 | 0.04 |
DOT |
BLBLIs | 0.07 | 0.045 | | |
Glycopeptides | − 0.20 | 0.02 | − 0.20 | 0.02 |
Clindamycin | − 0.21 | 0.07 | | |
- BLBLIs β-lactam/β-lactam inhibitors, DDD defined daily dose, DOT days of therapy, HO-CDI healthcare facility-onset C. difficile infection
- aVariables with P < 0.1 in the univariate analysis were included in the multivariate analysis
- bChanges in the incidence of HO-CDI according to antibiotic consumption
- cR-squared in multivariate analysis: 0.19 [DDD] and 0.22 [DOT]